Payment overview · 2025
General Payments
$1,130.28
55 reported records · 18 companies
Healthcare provider profile · identity verified
Tasha Brooks Dickerson, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · RICHMOND, VA · NPI 1255412052
Verified facts
What the public records show
CMS Open Payments records show Tasha Brooks Dickerson, M.D. received $1,130.28 in general payments during 2025 across 55 reported records.
Novo Nordisk Inc accounted for 22.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $251.31 | 22.2% | 12 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $115.57 | 10.2% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $104.76 | 9.3% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $101.01 | 8.9% | 6 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $99.06 | 8.8% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $86.37 | 7.6% | 5 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $53.09 | 4.7% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $52.02 | 4.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $49.50 | 4.4% | 3 | 2025 |
| Cleerly, Inc. | Unresolved — no canonical attribution shown | $37.59 | 3.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.85 | 3.3% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $28.19 | 2.5% | 1 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $23.83 | 2.1% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $23.13 | 2.0% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.50 | 1.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.30 | 1.6% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.52 | 1.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $13.68 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,130.28 | 55 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $119.47 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $115.57 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $115.57 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $104.76 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $104.76 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $99.06 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $73.29 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $67.54 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $66.07 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $53.09 | 3 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $52.02 | 2 | 2025 |
Source payment records
|
|||||
| Cleerly Ischemia Normalized: cleerly ischemia |
Device | Cleerly, Inc. | $37.59 | 1 | 2025 |
Source payment records
|
|||||
| Cleerly Labs Normalized: cleerly labs |
Device | Cleerly, Inc. | $37.59 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $36.85 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $35.04 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $32.41 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $29.80 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $28.19 | 1 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $23.83 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $23.13 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $19.50 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.09 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $16.52 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.94 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.78 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $13.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 243 | 71 |
| Atorvastatin Calcium | Atorvastatin Calcium | 179 | 58 |
| Hydrochlorothiazide | Hydrochlorothiazide | 162 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 121 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 105 | 35 |
| Lisinopril | Lisinopril | 94 | 46 |
| Metformin Hcl | Metformin Hcl | 89 | 25 |
| Levothyroxine Sodium | Levothyroxine Sodium | 85 | 23 |
| Metformin Hcl Er | Metformin Hcl | 73 | 19 |
| Pantoprazole Sodium | Pantoprazole Sodium | 67 | 25 |
| Furosemide | Furosemide | 62 | 15 |
| Trazodone Hcl | Trazodone Hcl | 61 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 56 | 20 |
| Losartan Potassium | Losartan Potassium | 55 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 51 | 13 |
| Sertraline Hcl | Sertraline Hcl | 45 | 12 |
| Potassium Chloride | Potassium Chloride | 44 | 11 |
| Simvastatin | Simvastatin | 43 | suppressed |
| Famotidine | Famotidine | 42 | 12 |
| Glipizide Er | Glipizide | 42 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 41 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 41 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | 12 |
| Januvia | Sitagliptin Phosphate | 38 | 11 |
| Omeprazole | Omeprazole | 37 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 36 | suppressed |
| Meloxicam | Meloxicam | 33 | suppressed |
| Alprazolam | Alprazolam | 31 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 31 | 14 |
| Gabapentin | Gabapentin | 29 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 29 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 29 | 13 |
| Methocarbamol | Methocarbamol | 28 | 12 |
| Baclofen | Baclofen | 26 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | suppressed |
| Ozempic | Semaglutide | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 20 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Allopurinol | Allopurinol | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 12 |
| Methimazole | Methimazole | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Azithromycin | Azithromycin | 13 | 13 |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Minoxidil | Minoxidil | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Easy Touch | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,130.28 · 55 records | Novo Nordisk Inc | AIRSUPRA, BREZTRI, Cleerly Ischemia, Cleerly Labs, Cologuard Collection Kit, FARXIGA, FFRct, GVOKE HYPOPEN, INSPIRE, JARDIANCE, Kerendia, LEQVIO, Leqembi, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, TRINTELLIX, The Cologuard Plus Collection Kit, UBRELVY, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error